Concepts (100)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heterocyclic Compounds, 3-Ring | 5 | 2025 | 85 | 0.740 |
Why?
|
| HIV Infections | 11 | 2025 | 5097 | 0.710 |
Why?
|
| Piperazines | 4 | 2025 | 82 | 0.690 |
Why?
|
| Oxazines | 4 | 2025 | 81 | 0.690 |
Why?
|
| Pyridones | 4 | 2025 | 100 | 0.680 |
Why?
|
| Dideoxynucleosides | 2 | 2023 | 29 | 0.620 |
Why?
|
| Anti-HIV Agents | 6 | 2025 | 1324 | 0.610 |
Why?
|
| Stavudine | 1 | 2017 | 78 | 0.550 |
Why?
|
| HIV | 1 | 2017 | 380 | 0.470 |
Why?
|
| Viral Load | 6 | 2025 | 819 | 0.420 |
Why?
|
| Drug Resistance, Viral | 2 | 2025 | 278 | 0.410 |
Why?
|
| HIV Integrase Inhibitors | 2 | 2025 | 33 | 0.290 |
Why?
|
| Emtricitabine | 3 | 2024 | 78 | 0.290 |
Why?
|
| HIV-1 | 4 | 2025 | 1260 | 0.280 |
Why?
|
| Tenofovir | 3 | 2024 | 171 | 0.270 |
Why?
|
| Female | 12 | 2025 | 9103 | 0.260 |
Why?
|
| Ritonavir | 2 | 2017 | 137 | 0.240 |
Why?
|
| Standard of Care | 1 | 2025 | 30 | 0.240 |
Why?
|
| Glucuronides | 1 | 2024 | 1 | 0.240 |
Why?
|
| Drug Interactions | 1 | 2024 | 31 | 0.230 |
Why?
|
| Child, Preschool | 5 | 2025 | 1748 | 0.230 |
Why?
|
| Infant | 6 | 2025 | 2244 | 0.230 |
Why?
|
| Adenine | 2 | 2023 | 91 | 0.230 |
Why?
|
| Postpartum Period | 1 | 2024 | 85 | 0.230 |
Why?
|
| Male | 9 | 2025 | 6754 | 0.220 |
Why?
|
| Bone Density | 1 | 2024 | 107 | 0.220 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2024 | 472 | 0.210 |
Why?
|
| Rifampin | 1 | 2024 | 197 | 0.210 |
Why?
|
| Humans | 12 | 2025 | 14537 | 0.210 |
Why?
|
| Lamivudine | 2 | 2023 | 89 | 0.190 |
Why?
|
| Treatment Outcome | 3 | 2025 | 889 | 0.190 |
Why?
|
| Viremia | 1 | 2019 | 66 | 0.160 |
Why?
|
| Pregnancy | 4 | 2024 | 1862 | 0.140 |
Why?
|
| Drug Combinations | 1 | 2017 | 42 | 0.140 |
Why?
|
| Streptococcus pneumoniae | 1 | 2020 | 336 | 0.140 |
Why?
|
| Child | 4 | 2025 | 2242 | 0.140 |
Why?
|
| Lopinavir | 1 | 2017 | 137 | 0.140 |
Why?
|
| Pneumococcal Infections | 1 | 2020 | 299 | 0.130 |
Why?
|
| Influenza Vaccines | 2 | 2020 | 144 | 0.130 |
Why?
|
| Anti-Retroviral Agents | 1 | 2019 | 551 | 0.120 |
Why?
|
| Infant, Newborn | 3 | 2025 | 1479 | 0.120 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2024 | 529 | 0.110 |
Why?
|
| Retrospective Studies | 1 | 2017 | 799 | 0.110 |
Why?
|
| Carbamates | 1 | 2014 | 12 | 0.110 |
Why?
|
| Organophosphates | 1 | 2014 | 9 | 0.110 |
Why?
|
| Sulfonamides | 1 | 2014 | 10 | 0.110 |
Why?
|
| South Africa | 4 | 2025 | 7596 | 0.110 |
Why?
|
| Benzoxazines | 2 | 2024 | 123 | 0.110 |
Why?
|
| Adolescent | 3 | 2025 | 2985 | 0.100 |
Why?
|
| Adult | 4 | 2024 | 5913 | 0.090 |
Why?
|
| Pneumonia | 1 | 2013 | 131 | 0.090 |
Why?
|
| Antibodies, Viral | 1 | 2013 | 284 | 0.090 |
Why?
|
| HIV Seropositivity | 1 | 2013 | 265 | 0.090 |
Why?
|
| Influenza, Human | 1 | 2013 | 374 | 0.080 |
Why?
|
| Prevalence | 2 | 2020 | 1192 | 0.060 |
Why?
|
| Young Adult | 2 | 2024 | 2498 | 0.060 |
Why?
|
| Spain | 1 | 2025 | 2 | 0.060 |
Why?
|
| Thailand | 1 | 2025 | 26 | 0.060 |
Why?
|
| Area Under Curve | 1 | 2024 | 20 | 0.060 |
Why?
|
| Zimbabwe | 1 | 2025 | 120 | 0.060 |
Why?
|
| Creatinine | 1 | 2024 | 53 | 0.060 |
Why?
|
| Absorptiometry, Photon | 1 | 2024 | 85 | 0.060 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2019 | 656 | 0.060 |
Why?
|
| Alkynes | 1 | 2024 | 117 | 0.060 |
Why?
|
| Cyclopropanes | 1 | 2024 | 123 | 0.060 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2024 | 118 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2024 | 244 | 0.050 |
Why?
|
| Tablets | 1 | 2023 | 39 | 0.050 |
Why?
|
| RNA | 1 | 2023 | 26 | 0.050 |
Why?
|
| Age Factors | 1 | 2024 | 370 | 0.050 |
Why?
|
| Genotype | 1 | 2025 | 442 | 0.050 |
Why?
|
| Biomarkers | 1 | 2024 | 327 | 0.050 |
Why?
|
| Alanine | 1 | 2021 | 31 | 0.050 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2021 | 24 | 0.050 |
Why?
|
| Gestational Age | 1 | 2021 | 80 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 279 | 0.040 |
Why?
|
| Pregnancy Outcome | 1 | 2021 | 117 | 0.040 |
Why?
|
| Nasal Lavage Fluid | 1 | 2020 | 2 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2020 | 45 | 0.040 |
Why?
|
| Self Report | 1 | 2019 | 114 | 0.040 |
Why?
|
| Africa South of the Sahara | 1 | 2019 | 353 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 435 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 411 | 0.040 |
Why?
|
| Risk Factors | 1 | 2019 | 1475 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 1422 | 0.030 |
Why?
|
| Furans | 1 | 2014 | 4 | 0.030 |
Why?
|
| HIV Protease Inhibitors | 1 | 2014 | 92 | 0.030 |
Why?
|
| Hemagglutination Inhibition Tests | 1 | 2013 | 23 | 0.030 |
Why?
|
| Virus Shedding | 1 | 2013 | 24 | 0.030 |
Why?
|
| Influenza A virus | 1 | 2013 | 28 | 0.030 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2013 | 31 | 0.030 |
Why?
|
| Influenza B virus | 1 | 2013 | 42 | 0.030 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2013 | 54 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2014 | 303 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2013 | 272 | 0.020 |
Why?
|
| Phylogeny | 1 | 2013 | 231 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 370 | 0.020 |
Why?
|
| Middle Aged | 1 | 2019 | 3601 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2014 | 967 | 0.020 |
Why?
|
| Hospitalization | 1 | 2013 | 418 | 0.020 |
Why?
|